Brainstorm Cell Therapeutics (BCLI) Bullish Stance Reiterated at Maxim Group Following ALS Study Data
Tweet Send to a Friend
Maxim Group analyst Jason Kolbert reiterated a Buy rating and $14 price target on Brainstorm Cell Therapeutics (NASDAQ: BCLI) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
